Bath & Body Works Jumps 3.5% on Citi Upgrade; Klarna Tumbles 26%
0h ago|5 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
bbwiklar
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. AiX is informational software — not investment advice. Past performance does not guarantee future results.
Shares of Bath & Body Works Inc. (BBWI) advanced in premarket trading on August 18, 2026, after Citi Research upgraded the stock, while Klarna Holding AB (KLAR) fell sharply following a disappointing guidance report. BBWI shares reached $20.08, a gain of 3.45%, as analyst Paul Lejuez shifted his recommendation to Buy from Neutral, citing a favorable risk/reward outlook. Conversely, Klarna stock dropped 25.88% to $15.41 after the payments firm projected full-year revenue and gross merchandise volume below market expectations. Amylyx Pharmaceuticals (AMLX) also saw extreme volatility, rallying 49.61% to $32.36 on positive clinical trial results for its experimental drug. Bloomberg reported the market-moving analyst action and corporate announcements driving the session.
The contrasting fortunes of Bath & Body Works and Klarna reflect two dominant themes in the current market environment: a reassessment of consumer discretionary names ahead of earnings season and heightened sensitivity to forward guidance in the fintech sector. For BBWI, the Citi upgrade arrives just one week before the company is scheduled to report quarterly results, amplifying the impact of the analyst's optimism. The retailer's stock has been volatile throughout 2026, making institutional endorsements particularly influential for short-term price direction.
Klarna's sharp decline underscores the market's low tolerance for guidance misses, especially for companies that have recently returned to profitability. The company noted it beat profit expectations for a second consecutive quarter, but investors focused squarely on the lowered top-line outlook. This reaction pattern is consistent with market behavior observed in the second quarter of 2026, where companies like Block Inc. (SQ) experienced similar sell-offs after providing cautious guidance despite quarterly beats.
The rally in Amylyx Pharmaceuticals represents a high-risk, high-reward binary event common in the biotechnology sector. The company announced that its late-stage trial for a treatment of post-bariatric surgery hypoglycemia met its primary endpoint. Such positive Phase 3 data often trigger significant re-ratings for small-cap biotech firms, as they de-risk the regulatory pathway and potential commercialization.
The broader macroeconomic backdrop features moderate consumer spending and persistent foreign exchange volatility, which Klarna directly cited as a headwind. These conditions create a stock-picker's market where company-specific news, such as analyst actions and clinical trial results, can generate outsized moves relative to major indices.
The premarket trading data as of 15:27 UTC today reveals the magnitude of these moves. Klarna (KLAR) traded down 25.88%, a decline of $5.39 from its previous close, within a range of $15.34 to $16.18. This drop significantly underperforms the Nasdaq Financial Index, which was flat in early trading. The sell-off erased approximately $2.5 billion from Klarna's market capitalization based on its outstanding share count.
Bath & Body Works (BBWI) saw more modest but still significant gains, rising 3.45% to $20.08. The stock traded between $19.15 and $20.19, indicating strong buying interest at the open. This upgrade-driven gain contrasts with the S&P 500 Consumer Discretionary sector's year-to-date performance of approximately 5%, suggesting BBWI may be playing catch-up.
Amylyx Pharmaceuticals (AMLX) was the standout performer, with its 49.61% surge translating to a gain of over $10 per share. The stock hit a session high of $32.81, nearing its 52-week peak. The trading volume for AMLX was multiples of its daily average, indicating intense speculative interest following the clinical news.
| Ticker | Price | Change (%) | Intraday Range |
|---|---|---|---|
| KLAR | $15.41 | -25.88% | $15.34 - $16.18 |
| BBWI | $20.08 | +3.45% | $19.15 - $20.19 |
| AMLX | $32.36 | +49.61% | $28.00 - $32.81 |
The volatility in these names is exemplified by the wide intraday ranges, particularly for AMLX, which saw a swing of over $4.80 per share. This level of movement is more than triple the average daily range for the S&P 500.
The Citi upgrade for Bath & Body Works signals a growing conviction among some analysts that the downside for specialty retailers is limited after a period of underperformance. The positive note could trigger a reassessment of peers like Ulta Beauty (ULTA) and L Brands' other holdings, as analysts look for similar risk/reound setups in the space. The immediate flow was decisively bullish for BBWI, with buy-side institutions likely accumulating positions ahead of next week's earnings report.
Klarna's guidance miss has negative implications for the broader buy-now-pay-later (BNPL) and fintech sector. Competitors such as Affirm Holdings (AFRM) and PayPal Holdings (PYPL) may face selling pressure as investors question the growth sustainability of consumer credit platforms amid economic uncertainty. The company's specific mention of volume softness in Germany, a key European market, raises concerns about regional economic health and its impact on transaction processors.
A counter-argument to the bearish Klarna thesis is that the company's continued profitability, even amid top-line pressures, demonstrates improved cost management. Value-oriented investors might view the steep sell-off as an overreaction, creating a potential entry point. However, the dominant positioning appears to be short-term momentum selling by growth-focused funds that prioritize revenue expansion above all else.
The Amylyx surge illustrates the capital allocation dynamics within healthcare sectors. The successful trial not only benefits AMLX shareholders but also increases investor appetite for other small-cap biotech firms with late-stage catalysts, potentially lowering the cost of capital for the broader sector. Hedge funds with dedicated healthcare strategies were likely covering short positions, adding to the upward pressure.
The primary immediate catalyst for Bath & Body Works is its quarterly earnings report, scheduled for the week of August 25, 2026. Investors will scrutinize management's commentary on foot traffic, margin trends, and holiday season inventory plans. Key technical levels to watch include the stock's 200-day moving average near $19.50, which now acts as support, and resistance around the $21.00 level, which has contained rallies since April.
For Klarna, the next significant event will be its next quarterly earnings release in November. Markets will monitor whether the company's revised guidance proves conservative or if further downward revisions are necessary. The $15.00 level is critical support; a sustained break below could trigger another leg down.
Amylyx Pharmaceuticals investors should watch for the company's regulatory filing strategy with the FDA regarding its new drug application. The timing of the submission and any request for Priority Review will be the next major valuation catalyst. Resistance is evident at the day's high of $32.81, while a hold above $30.00 would indicate sustained bullish conviction.
Klarna's stock dropped because investors prioritize future growth prospects over backward-looking results. While the company reported a profit beat for the second quarter, its guidance for full-year revenue and gross merchandise value fell short of analyst forecasts. The market perceived this guidance as an indication that growth is slowing more than anticipated, overshadowing the positive profit news. This is a common reaction in high-growth sectors like fintech, where valuations are heavily dependent on future expansion rates.
A primary endpoint is the main result that a clinical trial is designed to measure. It is the pre-specified, most important outcome used to determine whether an experimental treatment is effective. For Amylyx Pharmaceuticals, the primary endpoint for its hypoglycemia drug was likely a specific, measurable improvement in patients' blood sugar levels following bariatric surgery. Meeting the primary endpoint is a critical regulatory hurdle that significantly increases the probability of the drug eventually gaining FDA approval.
AiX is our free MetaTrader 4 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. XAUUSD breakout engine.
Trade 800+ global stocks & ETFs
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.